Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3)； analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors； polynucleotides encoding the polypeptides； vectors and host cells that embody the polynucleotides； pharmaceutical compositions and diagnostic reagents comprising the polypeptides； and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
